Evidence map›Paper›PMID 42554619›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Generalizable Strategies for the Synthesis of Cereblon-Recruiting PROTAC Prodrugs.

Aiden X Wang, Bin Liu, Elise M Ackerman, Yichen Xiang, Hung V-T Nguyen, Yivan Jiang, Angela N Koehler, Jeremiah A Johnson

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aiden X WangDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0001-6335-9836
Bin LiuDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Elise M AckermanDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Yichen XiangKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Hung V-T NguyenDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Yivan JiangDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Angela N KoehlerKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Jeremiah A JohnsonDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.ORCID https://orcid.org/0000-0001-9157-6491

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Organic nanoparticles for dual MRI-guided therapeutic selection and ovarian cancer drug deliveryR01CA220468 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jeremiah Allen Johnson · 2017 to 2026
$4.9M
CCSG Award for the Koch Institute P30-CA014051NCI NIH HHS 2R01CA220468-06A1NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA220468Yosemite-American Cancer Society Award YACS-24-1343208-01-YACS
6 · The paper itself

Abstract

Cereblon (CRBN)-recruiting PROTACs (proteolysis-targeting chimeras) are among the most clinically advanced degraders but remain challenging to chemically modify for translation to prodrug-based delivery strategies. Here, we report three orthogonal approaches-triazole quaternization, tertiary-amine alkylation, and installation of a hydroxyl linker-that enable chemoselective, high-yielding syntheses of CRBN-recruiting PROTAC prodrugs. These strategies allow incorporation of self-immolative linkers whose cleavage kinetics can be predictably tuned to release the parent PROTAC, which is demonstrated in the context of PEGylated macromonomer and bottlebrush prodrug macromolecular scaffolds. In multiple myeloma models, representative PROTAC-bottlebrush prodrugs (PROTAC-BPDs) induce cellular potency profiles that follow the designed PROTAC release rates, confirming that the observed protein degradation and cytotoxicity arise from effective prodrug linker cleavage. Collectively, this work establishes generalizable approaches for constructing prodrugs of CRBN-based PROTACs, expanding the synthetic space for targeted protein degradation and providing new design principles for controlling degrader activation, selectivity, and in vivo delivery.

Indexed as

Adaptor Proteins, Signal TransducingAntineoplastic AgentsProdrugsUbiquitin-Protein LigasesHumansProteolysisProteolysis Targeting ChimeraAdaptor Proteins, Signal TransducingAntineoplastic AgentsCRBN protein, humanProdrugsProteolysis Targeting ChimeraUbiquitin-Protein Ligasesalkylationcereblonchemistrycombinatorial chemistrycytotoxicitylinkermacromonomerprodrugprotein degradation

Identifiers

PMID42554619
PMCPMC13618278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.